Precision medicine: A tailored therapy for each tumor
Each tumor uses specific, individual biochemical pathways to grow and to escape natural defense mechanisms such as apoptosis or immune responses. These pathways are encoded in the tumors aberrant DNA. The abnormal genetic code in the tumor results in aberrant expression of genes and proteins.
Next Generation Sequencing today enables to determine the activity as well as mutations of all the genes in each individual tumor with great precision. By analyzing the mutations and other abberations such as copy nummber variations or fusion genes gene activity, the resulting abnormal pathways the tumor employs to survive can often be identified. Often, specific existing drugs that intervene with these pathways can be applied. This tumor-tailored treatment is referred to as Precision Medicine.
Currently cancer is treated according to its origin: a liver tumor like a liver tumor, a lung-tumor like a lung-tumor. However, an individual lung tumor can be more similar to a liver-tumor than to another lung tumor. In Precision Medicine not the origin but rather the specific metabolism of a particular tumor is decisive for its treatment.
Precision Medicine paves the way for individual, new and highly promising therapeutic options for each patient. Thus, this technology could become a game changer for every cancer patient. Thanks to our smart and powerful wet-lab techniques in combination with most accurate bioinformatics pipelines we quickly became experts in this exiting and and revolutionary field of precision medicine. We are proud to have convinced leading experts in the field with our approaches to chose us as partners for colaboration.
Precision Medicine is already applied in the most progressive hospitals in the USA and in Europe. However, because of its novelty and lack of expertise in most hospitals it is currently only available for a limited number of patients and also costs are still high. GenXPro strives to change this unfavorable situation by providing for each patient the chance to obtain the best suited treatment.
In contrast to most other approachaches, we combine gene expression analysis with knowledge about genetic abnormalities. Among the many mutated genes in a tumor, only a few are responsible for the disease and might not even play a role at all. By knowing their expression values, therapies can be focussed on the relevant targets and not on targets that are of no importance for the tumor.
Our approach determines also the “tumor mutation load” or “tumor mutation burden”, the number of mutations per megabase in the tumor DNA. This number is, together with gene expression data for checkpoint inhibitors and their receptors a key factor for the success of immunotherapies (see A.Ribas, NEJM, N Engl J Med 2015; 373:1490-1492).
Our MACE technology in combination with Exome Sequencing of the tumors gene coding DNA produces a highly accurate genetic profile and gene expression analysis of an individual tumor at optimal cost/benefit ratio.
Many cancer gene panels target only few genes, that are often not expressed in the tumor. Our profiles show exactly, which mutations the tumor has and which biochemical pathways it uses.
We exploit the enormous information available in public databases such as “The Cancer Genome Atlas” (TCGA), an initiative of the National Cancer Institute of the USA. These data bases contain genetic and clinical information about hundreds and thousands of tumors and cancer cell lines. If tumors with a characteristic gene activity profile or cell cultures with a similar expression pattern have already been successfully treated with a certain drug, the same drug can also be applied to an individual patient’s tumor. Also, the data can help to design new therapies which engage the immune system against relevant immunologically accessible mutated proteins that the tumor generates.
In the recent years we have developed and refined statistical and bioinformatics methods to identify the most important pathways and transcripts of an individual tumor with very high security. Our algorithms are constantly improved whenever additional data is available.
Altogether, our expertise that we have developed during 10 years of research and that we are constantly improving in publicly funded projects together with doctors and clinicians enables the doctor to choose a drug according to the patient’s individual needs.
Declaration of Non-Liability:
GenXPro is not accredited according to the German Gendiagnostik-Gesetz. Therefore, for the time being the company cannot and will not provide diagnostic services for legal reasons. All interaction between the company and customers with cancer solely aims at improving the knowledge on cancer genetics by research. Results eventually arising from this research may not be used as advice for making therapeutic decisions for legal reasons. Please contact us if you are a patient or a doctor, if you would like to learn more about our analyses.